Bibliography
- WELLBROCK C, KARASARIDES M, MARAIS R: The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. (2004) 5(11):875-885.
- BEERAM M, PATANAIK A, ROWINSKY EK: RAF: a strategic target for therapeutic development against cancer. J. Clin. Ocol. (2005) 23(27):6771-6790.
- SRIDHAR SS, HEDLEY D, SIU LL: RAF kinase as a target for anticancer therapeutics. Mol. Cancer Ther. (2005) 4(4):677-685.
- BACCARINI M: Second nature: biological functions of the RAF-1 ‘kinase.’ FEBS Lett. (2005) 579(15):3271-3277.
- O’NEILL E, KOLCH W: Conferring specificity on the ubiquitous RAF/MEK signalling pathway. Br. J. Cancer (2004) 90(2):283-288.
- PAN J, YEUNG S-CJ: Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. (2005) 65(20):9109-9112.
- YUEN ST, DAVIES H, CHAN TL et al.: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. (2002) 62(22):6451.
- DAVIES H, BIGNELL GR, COX C et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-954.
- LORUSSO P, KRISHNAMURTHI S, RINEHART JR et al.: A Phase 1 – 2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J. Clin. Oncol. (2005) 23(16S). Abstract 3011.
- SMITH RA, DUMAS J, ADNANE L, WILHELM S: Recent advances in the research and development of RAF kinase inhibitors. Curr. Topics Med. Chem. (2006) 6:(In Press).
- DUMAS J: Protein kinase inhibitors from the urea class. Curr. Opin. Drug Discov. Dev. (2002) 5(5):718-727.
- DUMAS J, SMITH RA, LOWINGER TB: Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr. Opin. Drug Discov. Dev. (2004) 7(5):600-616.
- LOWINGER TB, RIEDL B, DUMAS J, SMITH RA: Design and discovery of small molecules targeting RAF-1 kinase. Curr. Pharm. Des. (2002) 8(25):2269-2278.
- AMIRI A, AIKAWA M, DOVE N et al.: CHIR-265 is a potent selective inhibitor of c-RAF/B-RAF/mutB-RAF that effectively inhibits proliferation and survival of cancer cell lines with Ras/RAF pathway mutations. Proc. Am. Assoc. Cancer Res. Washington DC, USA (2006) Abstract 4855.
- HEIMBROOK DC, HUBER HE, STIRDIVANT SM et al.: Identification of potent, selective inhibitors of RAF protein kinase. Proc. Am. Assoc. Cancer Res. New Orleans, USA (1998) Abst. 3793.
- LACKEY K, CORY M, DAVIS R et al.: The discovery of potent cRAF1 kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10(3):223-226.
- HALL-JACKSON CA, EYERS PA, COHEN P et al.: Paradoxical activation of RAF by a novel RAF inhibitor. Chem. Biol. (1999) 6(8):559-568.
Patents
- MERCK PATENT GMBH: WO2005047283 (2005).
- CHIRON CORP.: WO2005037285 (2005).
- MERCK PATENT GMBH: WO2005042520 (2005).
- MERCK PATENT GMBH: WO2005004863 (2005).
- SMITHKLINE BEECHAM PLC: WO2003022837 (2003).
- GENOMICS INSTITUTE OF THE NOVARTIS RES. FDN: WO2005039486 (2005).
- EXELIXIS, INC.: WO2005112932 (2005).
- EXELIXIS, INC.: WO2003093297 (2003).
- EXELIXIS, INC.: WO2004006846 (2004).
- EXELIXIS, INC.: WO2004050681 (2004).
- EXELIXIS, INC.: WO2004083235 (2004).
- EXELIXIS, INC.: WO2004091480 (2004).
- EXELIXIS, INC.: WO2004092196 (2004).
- EXELIXIS, INC.: WO2005020921 (2005).
- EXELIXIS, INC.: WO2005030140 (2005).
- EXELIXIS, INC.: WO2005039506 (2005).
- EXELIXIS, INC.: WO2005040355 (2005).
- EXELIXIS, INC.: WO2005097765 (2005).
- EXELIXIS, INC.: WO2005117909 (2005).
- EXELIXIS, INC.: WO2006014325 (2006).
- EXELIXIS, INC.: WO2006033943 (2006).
Websites
- http://www.bionetresearch.co.uk/ screenin.htm Key organics website.
- http://www.exelixis.com/pipeline.shtml Exelixis website.